ArticlePloS one2021
Association between sarcopenia level and metabolic syndrome.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Correlation between low handgrip strength and metabolic syndrome in older adults: a systematic review.Archives of endocrinology and metabolism · 2024Pooled it
- Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Incremental diagnostic value of multiregional single-slice CT muscle areas over L3 for sarcopenia: a deep learning-based segmentation study.Skeletal radiology · 2026Article
- The impact of metabolic syndrome on changes in trunk muscle CSA: a 10-year longitudinal study.Journal of bone and mineral metabolism · 2026Article
- Article
- Association between appendicular lean mass-to-body weight ratio and metabolic syndrome in community-dwelling older adults in Taiwan: A cross-sectional study.The Journal of international medical research · 2026Article
- Global prevalence of metabolic syndrome among individuals with sarcopenia: a systematic review and meta-analysis of 72,129 patients.Diabetology & metabolic syndrome · 2026Review
- Evaluation of Prevalence and Risk Factors of Possible Sarcopenia Based on SARC-F in Adults Over 60 in Tegucigalpa, Honduras: A Cross-Sectional Study.Health science reports · 2026Article
- Association between estimated glucose disposal rate and metabolic syndrome in older adults with sarcopenia.Frontiers in nutrition · 2026Article
- Sarcopenia (defined by low muscle mass) as a predictor of disease progression and mortality in cardiovascular-kidney-metabolic syndrome.Diabetology & metabolic syndrome · 2025Article
- The prognostic value of small psoas muscle area in patients undergoing mitral transcatheter edge-to-edge repair.Cardiovascular intervention and therapeutics · 2025Article
- Association between sarcopenia and components of metabolic syndrome among Chinese older adults: a population-based longitudinal study using CHARLS.BMC public health · 2025Article
- Ultrasound evaluation of muscles in older patients with metabolıc syndrome.Irish journal of medical science · 2025Article
- From muscle quality to metabolic health: investigating the association between muscle quality index and metabolic syndrome in adults.Diabetology & metabolic syndrome · 2025Article
- Relationship between atherosclerotic burden and sarcopenia in U.S. adults: A cross-sectional study based on the NHANES database.Scientific reports · 2025Article
- Prevalence and coexistence of locomotive syndrome with reduced mobility and metabolic syndrome: a cross-sectional study of 35,059 Japanese adults.Scientific reports · 2025Article
- Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.Metabolites · 2025Review
- A nomogram to predict sarcopenia in middle-aged and older women: a nationally representative survey in China.Frontiers in public health · 2025Article
- Comparison of nutrients and ultra-processed food consumption between different phenotypes defined by abdominal obesity and sarcopenia.Frontiers in nutrition · 2025Article
- Grip Strength, Anthropometric Indices, and Their Combination in Screening for Metabolic Syndrome in the Korean Population.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMetabolic syndrome (MetS) increases the risk of diabetes mellitus (DM), cardiovascular disease (CVD), cancer, and mortality. Sarcopenia has been reported as a risk factor for MetS, non-alcoholic fatty liver disease, and CVD. To date, the association between sarcopenia and MetS has been investigated. However, there have been few studies on the dose-response relationship between sarcopenia and MetS. We investigated the association between sarcopenia and the prevalence of MetS. We also aimed to analyze the dose-response relationship between skeletal muscle mass and the prevalence of MetS.
methodsWe enrolled 13,620 participants from October 2014 to December 2019. Skeletal muscle mass was measured using bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM) was divided by body weight (kg) and was expressed as a percentage (ASM x 100/Weight, ASM%). The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. Linear regression and logistic regression analyses were used to compare the clinical parameters according to ASM%, adjusted for age, sex, obesity, hypertension (HT), DM, dyslipidemia (DL), smoking, alcohol intake, and C-reactive protein (CRP). Multiple logistic regression analysis was performed to determine the risk of MetS in each group.
resultsA dose-response relationship was identified between ASM% and MetS. Sarcopenia was associated with an increased prevalence of MetS. After adjustment for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, sarcopenia remained significantly associated with MetS. For each 1 quartile increment in ASM%, the risk of MetS decreased by 56% (P< 0.001). After adjusting for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, the risk of MetS decreased by 25% per 1Q increment in ASM% (P < 0.001).
conclusionsSarcopenia by BIA is independently associated with the risk of MetS and has a dose-response relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.